1. Home
  2. PROK vs DBI Comparison

PROK vs DBI Comparison

Compare PROK & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProKidney Corp.

PROK

ProKidney Corp.

N/A

Current Price

$0.91

Market Cap

359.4M

Sector

Health Care

ML Signal

N/A

Logo Designer Brands Inc.

DBI

Designer Brands Inc.

N/A

Current Price

$6.78

Market Cap

344.6M

ML Signal

N/A

Company Overview

Basic Information
Metric
PROK
DBI
Founded
2015
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Clothing/Shoe/Accessory Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
359.4M
344.6M
IPO Year
2021
2005

Fundamental Metrics

Financial Performance
Metric
PROK
DBI
Price
$0.91
$6.78
Analyst Decision
Buy
Hold
Analyst Count
6
2
Target Price
$6.50
★ $6.75
AVG Volume (30 Days)
★ 1.1M
497.2K
Earning Date
11-13-2026
12-08-2026
Dividend Yield
N/A
★ 2.97%
EPS Growth
N/A
★ 15.00
EPS
N/A
★ 0.34
Revenue
$893,000.00
★ $2,892,671,000.00
Revenue This Year
N/A
$0.73
Revenue Next Year
N/A
$2.01
P/E Ratio
★ N/A
$19.71
Revenue Growth
★ 1075.00
N/A
52 Week Low
$1.29
$3.29
52 Week High
$2.95
$9.17

Technical Indicators

Market Signals
Indicator
PROK
DBI
Relative Strength Index (RSI) 25.21 63.37
Support Level N/A $5.91
Resistance Level $2.01 $7.59
Average True Range (ATR) 0.14 0.31
MACD -0.03 0.06
Stochastic Oscillator 5.16 79.78

Price Performance

Historical Comparison
PROK
DBI

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

About DBI Designer Brands Inc.

Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in two reportable segments: the Retail segment and the Brand Portfolio segment. The Retail segment, which derives key revenue, operates the DSW Designer Shoe Warehouse ("DSW") banner through its direct-to-consumer stores and e-commerce sites in the United States ("U.S.") and Canada, and the Shoe Co. and Rubino banners through its direct-to-consumer stores and e-commerce sites in Canada. The Brand Portfolio segment principally earns revenue from the wholesale of its exclusive and licensed brands to retailers, its Retail segment, and international distributors, and the sale of its Vince Camuto, Keds, and Topo brands through direct-to-consumer e-commerce sites.

Share on Social Networks: